JPS60141281A - Method and apparatus for producing granule of microorganism - Google Patents
Method and apparatus for producing granule of microorganismInfo
- Publication number
- JPS60141281A JPS60141281A JP24539883A JP24539883A JPS60141281A JP S60141281 A JPS60141281 A JP S60141281A JP 24539883 A JP24539883 A JP 24539883A JP 24539883 A JP24539883 A JP 24539883A JP S60141281 A JPS60141281 A JP S60141281A
- Authority
- JP
- Japan
- Prior art keywords
- nozzle
- protective film
- solution
- coagulation
- granules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
【発明の詳細な説明】
及び装置に関するもので、特にビフィズス１胞の如き田
にあっては経口摂取された後も、胃液による死滅が少な
くて腸内に達する顆粒状の菌体の製造方法釜にそれに適
した装置を提供するものである。[Detailed Description of the Invention] and an apparatus, and a method for producing granular bacterial cells that are less likely to be killed by gastric juice and reach the intestine even after oral ingestion, especially in the case of Bifidus 1 cells. The aim is to provide equipment suitable for this purpose.
従来より細菌、酵母等多くの微生物全保存する場合菌体
を乾燥し保存する方法が講じらｉしている。BACKGROUND ART Conventionally, when preserving the entirety of many microorganisms such as bacteria and yeast, methods have been used to dry and preserve the microorganisms.
乾燥は培養液より分離した菌体をそのま＼、或いはこれ
にでん粉、乳糖、告白質又は有機、無機の塩類を加え、
低温通風乾燥、真空乾燥或いは凍結乾燥により水分１０
部以下となるようにするものである。例えば成人腸内に
不足するとされているビフィズス菌は生の″！！５飲料
又はヨーグルトに混合して経口摂取することも可能であ
るが、保存に適しない所から乾燥し他の食品と混合する
方法が広く行なわれ、特公昭５８−４６２９３号公報に
は含水率４％以下のでん粉、でん扮加水分解物又は蛋白
質の１種又は２１１■以上の打錠用基礎配合物と、凍結
乾燥したビフィズス＝１混合し打錠してビフィズス囚含
有錠菓を製造する方法が開示され、特開昭５８−１４９
６７号公報にはビフィズス菌体と生でん粉を混合し凍結
乾燥してビフィズス曙の生存率を高める方法が開示され
ている。For drying, the bacterial cells isolated from the culture solution can be dried as is, or starch, lactose, sugar, or organic or inorganic salts can be added to them.
Moisture is reduced to 10% by low temperature ventilation drying, vacuum drying or freeze drying.
1. For example, Bifidobacterium, which is thought to be lacking in the adult intestines, can be ingested raw by mixing it with drinks or yogurt, but it can be dried from places that are not suitable for storage and mixed with other foods. This method is widely used, and Japanese Patent Publication No. 58-46293 discloses that a base formulation for tableting containing one or more of starch, starch hydrolyzate or protein with a moisture content of 4% or less and freeze-dried A method for producing a tablet confectionery containing bifidus by mixing 1 bifidus and tableting is disclosed, and Japanese Patent Application Laid-Open No. 58-149
Publication No. 67 discloses a method for increasing the survival rate of Bifidobacteria by mixing Bifidobacterial cells and raw starch and freeze-drying the mixture.
」二記方法により製造された乾燥ビフィズス菌は、何れ
も相当の保存性全有するが基本的に粉状であり空気との
接触面績が大きいので保存には特別の配慮を必要とする
とか、体内に取入れられると均一に分散して胃液の影響
を受けて相当数の因が死滅し腸内に達する割合は少ない
等の欠点がある。Dried bifidobacteria produced by the method mentioned above have a considerable shelf life, but they are basically in powder form and have a large contact area with air, so special consideration is required for preservation. When taken into the body, it is dispersed uniformly and is affected by gastric juices, killing a considerable number of bacteria, and it has drawbacks such as a small percentage reaching the intestines.
又、乳酸菌、酵母菌等を造粒法、押し出し成形法等で成
形し、公知の方法で乾燥しても保存性に多くの問題があ
ることは周知の通りである。Furthermore, it is well known that even if lactic acid bacteria, yeast, etc. are molded by granulation, extrusion, etc. and dried by known methods, there are many problems with storage stability.
本発明者等は上記乾燥方法の欠点を根本的に解決し、取
扱いが容易でしかも保存性のよい乾燥函体を得んと研究
した結果、従来の乾燥助剤の如く単に菌体表面に付着さ
せるのでなく保護膜形成溶液中に菌体を懸濁させ、これ
を凝固用塩類溶液と反応させて凝固させ菌体表面に均一
な保護膜全形成させるとよいことに着目し、先づ生菌体
と保護膜形成溶液を均一に混合し、混合液全凝固用塩類
溶液に注入して塊状に凝固させ、得られた凝固物を分離
して乾燥し、必要に応じて体温以」二の融点をもつ油脂
でコーティングする方法並びにそれに適した装置全開元
することに成功したのである。The present inventors conducted research to fundamentally solve the drawbacks of the above drying method and obtain a drying box that is easy to handle and has good storage stability. Focusing on the fact that it is better to suspend the bacterial cells in a protective film-forming solution instead of letting them dry and then react with a coagulating salt solution to solidify and form a uniform protective film on the surface of the bacterial cells, we first The body and the protective film forming solution are uniformly mixed, and the mixture is poured into a saline solution for total coagulation to coagulate into a lump.The obtained coagulated product is separated and dried, and if necessary, the melting point is lower than body temperature. They succeeded in developing a method for coating with oils and fats that have a high viscosity, as well as a device suitable for the process.
本発明に１史用する囚としては、乳Ｉ−１々ｍ１酵母菌
等食品、薬品Ａ造又は加工用或いは一般工業用微生物が
使用でき、特にビフィズス菌の如く経口摂取する微生物
に応用して好適である。ビフィズス菌としては例えばビ
フィドバクテリウム・イン７７ ンテス（Ｂｉｆ ｉｄ
ｌ〕ａｃｔｅｒｉｕｍ １ｎｆａｎｔｉｓ ）、ビフィ
ドバクテリウム・ロンガム（Ｂｉｆｉｄｂａｃｔｅｒｉ
ｕｍ ｌｏｎｇｕｍ ）、ビフィドバクテリウム・アド
レッセンチス（Ｉ３百ｉｄｂａｃｔｅｒｉｕｍ ａｄｌ
ｅｃｓｅｎｔｉｓ ） を挙げることができる。Microorganisms used in the present invention include milk I-1m1 yeast and other microorganisms used for food, drug A production or processing, or general industrial use. suitable. Examples of bifidobacteria include Bifidobacterium intes (Bifidobacterium intes).
l]acterium 1nfantis), Bifidobacterium longum (Bifidobacterium longum)
um longum), Bifidobacterium adl.
ecsentis).
上記の１散生物は糖類、塩類及び生長素を含む天然又は
合成の培養基で培養し、培養後は通常遠心分離機で函体
分離全行ない濃縮し、濃縮物に水又は生理的食塩水を加
えて稀釈洗滌し、再度遠心分離する。上記洗滌操作は菌
体の濃縮度により差があるが通常２〜３回繰返すとよい
。得られた洗滌画体は培地成分が十分除去され異臭の少
ない菌体となるのでそのま＼使用してもよ覧、場合によ
っては更に脱水して使用してもよいものである。The above-mentioned 1. spheroids are cultured in a natural or synthetic culture medium containing sugars, salts, and growth factors, and after culturing, the box is usually separated and concentrated using a centrifuge, and water or physiological saline is added to the concentrate. Dilute, wash, and centrifuge again. The above-mentioned washing operation may be repeated 2 to 3 times depending on the degree of concentration of the bacterial cells. The obtained washed image body has the culture medium components sufficiently removed and becomes a bacterial cell with little off-flavor, so it can be used as is, or may be further dehydrated in some cases.
又、前記菌体と混合する保護膜形成溶液にはアルギン酸
ソーダ、アルギン酸カリ、ペクチン、グルコマンナンの
如りカルシーームイオンの如き金浦イオンと結合して菌
体表面に保護膜を形成する物質ヲ含んでおり、これにで
ん粉、デキストリン、蔗糖、グルタミン酸ナトリウム、
アスコルビン酸ナトリウム等調湿機能全有し、乾燥に際
して急激な脱水のショック全防止したり酸化を防止する
物質を添加するとよい。そのような混合物の組成例とし
ては、例えば固形物としてビフィズス酷体５〜１０部、
でん粉１０〜５０部、アルギン酸ナトリウム０１〜１０
部、及びグルタミン酸ナトリウム０５〜２０部、アスコ
ルビン酸ナトリウム０５〜１０部を含む！ｌ’！ ｒＡ
液を挙げることができる。In addition, the protective film forming solution mixed with the bacterial cells contains a substance such as sodium alginate, potassium alginate, pectin, or glucomannan that forms a protective film on the surface of the bacterial cells by binding with Gimpo ions such as calcime ions. It contains starch, dextrin, sucrose, monosodium glutamate,
It is recommended to add a substance that has a full humidity control function such as sodium ascorbate, completely prevents sudden dehydration shock during drying, and prevents oxidation. Examples of the composition of such a mixture include, for example, 5 to 10 parts of bifidus as a solid;
Starch 10-50 parts, sodium alginate 01-10
part, and 05-20 parts of sodium glutamate and 05-10 parts of sodium ascorbate! l'! rA
Examples include liquids.
又前記凝固用塩類溶液としては前記保護膜形成溶液の主
成分と結合して自体表面に被膜を形成させる機能を有す
る物質が使用され、実用的には菌体を死滅させず、人体
に無害な乳酸カルシウム、塩化カルシウム等の中性の５
〜２５°Ｃで１％程度の溶液が使用される。The coagulating salt solution used is a substance that has the function of combining with the main component of the protective film-forming solution to form a film on its surface, and in practical terms it does not kill bacterial cells and is harmless to the human body. Neutral 5 such as calcium lactate and calcium chloride
A solution of the order of 1% at ~25°C is used.
以下ビフィドバクテリウム・ロンガム（Ｂｉｆｉｄｂａ
ｃｔｅｒｉｕｍ ｌｏｎｇｕｍ ）−２上記要領で分離
し、ビフ４ズス１羽顆粒−ｆｃｍ造する場合の例を添付
の図面により説明する。図中１は原料混合槽全示し、そ
の内部にはｍ拌ＶｊＰ、２を備えビフィズス菌体とアル
ギン酸ナトリウム、でん粉、アスコルビン酸ナトリウム
、グルタミン酸ナトリウムヲ削記割合で入れ均一に混合
する。このとき混合物Ａの粘度は通常２００ＣＩ）程度
である。得られた混合物Ａは次いでポンプ３を介して混
合物貯槽４に移行させる。Bifidobacterium longum (Bifidba)
cterium longum)-2 in the above-mentioned manner and producing granules of 4 pieces of bif (1 bird)-fcm will be explained with reference to the attached drawings. In the figure, 1 shows the entire raw material mixing tank, inside which is equipped with m stirring VjP and 2, bifidobacterial cells, sodium alginate, starch, sodium ascorbate, and sodium glutamate are added in the proportions shown and mixed uniformly. At this time, the viscosity of mixture A is usually about 200 CI). The resulting mixture A is then transferred via pump 3 to mixture storage tank 4 .
貯槽４は密閉型であり、上部には調圧装置としてのエア
ーコンプレッサー５と連通ずる配管６と調圧伸６′を設
け、常時適当な圧力例えば、１１〜．３・ｋｇ／−の圧
力で貯槽４よジの押出圧がかけられるようにしておる。The storage tank 4 is of a closed type, and the upper part thereof is provided with a pipe 6 communicating with an air compressor 5 as a pressure regulating device and a pressure regulating extension 6', so that an appropriate pressure, e.g. An extrusion pressure of 3 kg/- is applied to the storage tank 4.
又貯槽４の下部には攪拌機７全備え４体、でん粉等が沈
澱するのを防止する。更に貯・：曹４の所望の位置に配
゛Ｕ８を連通させ、配管８の他端は多数の分配管９に開
口させである。この分配管９には多数のノズル１０を下
方に向けて取付けてあり、該ノズル１０の内径は１罷以
下、特に０．２〜０．５ ｍｍの範囲がよい。更にそれ
ぞれのノズル１０にはパルプ１１全設け、流量全調節し
たシ噴射を停止できるようしておくとよい。Further, four stirrers 7 are provided at the bottom of the storage tank 4 to prevent starch and the like from settling. Further, a pipe U8 is connected to a desired position of the storage tank 4, and the other end of the pipe 8 is opened to a large number of distribution pipes 9. A large number of nozzles 10 are attached to the distribution pipe 9 facing downward, and the inner diameter of the nozzles 10 is preferably one thread or less, particularly in the range of 0.2 to 0.5 mm. Further, it is preferable that each nozzle 10 is provided with all the pulp 11 and that the injection can be stopped after fully adjusting the flow rate.
上記構成によシ貯槽４内はエヤーコンプレッサー５によ
り加圧されているので混合物Ａはノズル１０の先端より
射出することになるが射出量はエヤーコンプレッサー５
の圧力やバルブ１１の調節によって調整可能でβるがエ
ヤーコンプレッサー５の代りに配管８の途中にポンプそ
の他の噴出量を調節できる装置を設けてもよいものであ
る。According to the above configuration, the inside of the storage tank 4 is pressurized by the air compressor 5, so the mixture A is injected from the tip of the nozzle 10, but the amount of injection is controlled by the air compressor 5.
The pressure can be adjusted by adjusting the pressure of the air and the valve 11, but instead of the air compressor 5, a pump or other device capable of adjusting the amount of ejection may be provided in the middle of the pipe 8.
ノズル１０の下方には凝固液槽１２を設け、その中に乳
酸カルシウム、あるいは塩化カルシウムの溶液を入れ凝
固液Ｂとする。又−側にオーバーフロー用樋１３を設け
、他側には凝固液貯槽１４と定量ポンプ１５を介して凝
固液Ｂを供給できるようにし、液面が前記ノズル１０の
下端より約３〜１０Ｃｒｎ下に位置するようにする。A coagulating liquid tank 12 is provided below the nozzle 10, and a solution of calcium lactate or calcium chloride is put therein to form a coagulating liquid B. Further, an overflow gutter 13 is provided on the - side, and the coagulating liquid B can be supplied to the other side via a coagulating liquid storage tank 14 and a metering pump 15, so that the liquid level is approximately 3 to 10 cr below the lower end of the nozzle 10. position.
このためノズル１０よりの混合物Ａは常に一定条件で射
出され凝固液槽１２にて短秒時に凝固し粒状と々って沈
下する。このとき、混合物Ａ中の固体はアルギン酸ソー
ダ溶液中に均一に懸濁しているので前記粒子の表１川が
先ずカルシウムイオンと接し瞬間的に被膜全形成し漸次
カルシウムイオンの浸入により内部の国体も被膜を形成
するので全体は固化する。Therefore, the mixture A from the nozzle 10 is always injected under constant conditions, solidifies in a short period of time in the coagulating liquid tank 12, and settles in granular form. At this time, since the solids in mixture A are uniformly suspended in the sodium alginate solution, the particles first come into contact with the calcium ions, instantly forming a complete film, and gradually the calcium ions penetrate inside the body. A film is formed and the whole solidifies.
ノズル１０よりの押し出し圧はノズル１０の口径、混合
物への組成及びノズル１０と液面との間隔によシ調節す
るのがよいが、前記条件を調節することにより射出ｉｆ
加減して微細な顆粒から大きい顆粒まで所望の大きさの
顆粒を製造できる。The extrusion pressure from the nozzle 10 is preferably adjusted depending on the diameter of the nozzle 10, the composition of the mixture, and the distance between the nozzle 10 and the liquid surface.
Granules of any desired size, from fine granules to large granules, can be produced by controlling the amount.
若し、押し出し圧が強すぎたシノズルと液面との距離が
不足すると混合物Ａは顆粒とすることはできず連続した
棒状となるので注意を要する。このようにして混合物Ａ
は互にくっつくことのない凝固粒子Ｃとなって下方に沈
澱する。If the extrusion pressure is too strong and the distance between the nozzle and the liquid level is insufficient, the mixture A cannot be made into granules but becomes continuous rod-shaped, so care must be taken. In this way, mixture A
become coagulated particles C that do not stick together and settle downward.
上記凝固粒子Ｃ２取出すため、凝固液Ｂの流れと直角方
向に２４〜３２メツシーのスクリーン１．６を走行させ
、プリー１７ 、１．７・・・により凝固槽１２を囲繞
すると共にスクリーン１６の排出側には樋１８を設は上
方に設けたノズル１９より水を噴射して洗滌するように
しである。乙のため凝固７位子Ｃは洗滌され、更にスク
リーン］６が回動すると下方に向きを変え容器２０の中
に落下するが、尚付着する凝固粒子Ｃはスクリーン１６
の戻り（ｎ１１裏側に設けた空気吹き出しノズル２１よ
りの気流により除去し、全部容器２０中に回収する。In order to take out the coagulated particles C2, a screen 1.6 of 24 to 32 meshes is run in a direction perpendicular to the flow of the coagulated liquid B, and the coagulation tank 12 is surrounded by pulleys 17, 1.7... and the screen 16 is discharged. A gutter 18 is provided on the side so that water can be sprayed from a nozzle 19 provided above for cleaning. As a result, the coagulated particles C are washed, and when the screen 6 rotates, the direction changes downward and falls into the container 20, but the coagulated particles C still attached are washed away by the screen 16.
(removed by the airflow from the air blowing nozzle 21 provided on the back side of n11, and all collected into the container 20.
回収された凝固粒子Ｃは多量の水分を含んでおり、その
ま＼では保存力に乏しいので次いで乾燥する。乾燥は真
空乾燥法、凍結乾・喋法或いは不活性ガス等による通風
乾燥法が採用でき、乾燥後の水分は１〜５チ程度の顆粒
とするのがよい。The recovered coagulated particles C contain a large amount of water and have poor preservability if left as is, so they are then dried. For drying, a vacuum drying method, a freeze-drying method, a drying method using an inert gas, etc. can be used, and the moisture content after drying is preferably about 1 to 5 grams.
」二記方法により得た顆粒は第３図で油脂層に）を除い
た構造を有し、１体（イ）及びでん粉（ロ）の表面がア
ルギン岐カルシウムの被膜（ハ）で被覆されており、ノ
ズル１０の内径より２〜３倍の径に膨化した構造を有す
るが、図より判明する如〈従来のように菌体と乾燥助剤
ヲ幌；械的に混合したものに比べ被覆は完全でしかも均
一であり被膜・０層も極めて薄いので保存力が著しく向
上するほか顆粒状であるから取扱いも朗利である。The granules obtained by the method described in 2 have a structure in which the oil and fat layer in Fig. 3 are excluded, and the surfaces of the granules (a) and starch (b) are coated with a film of alginated calcium (c). It has a structure in which the diameter is swollen to 2 to 3 times the inner diameter of the nozzle 10, but as can be seen from the figure, (as in the conventional case, the bacterial cells and drying aid are mixed together; Since it is complete and uniform, and the coating/zero layer is extremely thin, it has a significantly improved storage capacity, and is easy to handle because it is in a granular form.
次に実施例１により得た一体顆粒をアルミ箔で包み室温
及び３７°Ｃで保存したときの生困数の成績を第１衣（
Ｃ示す。Next, the integral granules obtained in Example 1 were wrapped in aluminum foil and stored at room temperature and 37°C.
Show C.
第 １ 表
本発明の方法により得た顆粒はそのま＼経口摂取するこ
とができるし、他の食品と混合して摂取してもよく、更
には他の作品の加工や工業用目的に使用できるものであ
る。経口隅取後１葛体はアルギンｊ液カル／ウムでイ皮
覆されているので胃液により死滅することは少ないが、
更に死滅を少なくするには函体顆粒全油脂でコーティン
グすることが望ましい。使用する油脂は従来改生物のコ
ーティングに・１吏用されている低融点の油脂は１更用
できず、人間の体温で可解しない高１′Ｘ独点の油１］
百で、例えば３７°Ｃ〜４３℃の、Ｉ訓点をもつ硬化油
である。Table 1 The granules obtained by the method of the present invention can be taken orally as is, mixed with other foods, and further used for processing other products or for industrial purposes. It is something. After oral extraction, the kudzu body is covered with alginic liquid Cal/Um, so it is unlikely to be killed by gastric juice, but
In order to further reduce mortality, it is desirable to coat the box granules with whole oil and fat. The oil and fat used is a low-melting point oil that is conventionally used for coating modified materials, but cannot be reused, and a unique high-1'X oil that does not dissolve at human body temperature.
It is a hydrogenated oil with an I rating, for example 37°C to 43°C.
油脂のコーティングは常法により行うことができるが流
動層造粒コーティング装置全１更用すると便利である。Coating with oil or fat can be carried out by a conventional method, but it is convenient to use one fluidized bed granulation coating device.
該装置は下方より気体を送り顆粒を流動させながら油脂
を噴７．コ尋しコーティングする方法であるが、コーテ
ィングにより胃液に対する抵抗が著しく向上し、殆んど
の菌体は腸内に達する。The device sends gas from below to fluidize the granules and spray oil and fat7. This coating method significantly improves resistance to gastric juices, and most of the bacteria reach the intestines.
今その例を実験例で示す。An example of this will now be shown with an experimental example.
実験は実施例１の方法で製造したビフィズス１頭粒全流
動層造粒コーティング装置フローコーターｐＬｏ−５型
（商品名）金用い、ビフィズス菌顆粒２ ｋｇに対しＪ
！１１ 、改４０℃の硬化油８００２全４５℃でｉ、ｉ
！Ｉｔ解し５０°Ｃの気流中に噴霧して行なった。The experiment was carried out using a full fluidized bed granulation coating device Flow Coater pLo-5 model (trade name) produced by the method of Example 1, and 2 kg of bifidobacteria granules.
! 11, modified 40℃ hardened oil 8002 i, i at 45℃
! The test was carried out by spraying into an air stream at 50°C.
その結果得られたコーテイング物は第３図に示すように
菌体（イ）とでん粉（ロ）の顆粒表面に油脂層に）が成
層した駄馬になり、このコーテイング物全人工的に調製
した胃液（食塩０２ヂ、ペプシン０．３２係を含み塩酸
でｐ Ｈ１，５にしたもの）に加え、３７°Ｃの恒温槽
中で１〜５時間攪陣しながら反応させた。反１；＋Ｔｔ
後ｐＨ７，０となし常法によりビフィズス生閑数を測定
した。その結果全第２表に示す。As shown in Figure 3, the resulting coated product becomes a stag with a layer of bacterial cells (a) and starch (b) on the surface of the granules (oil and fat layer). (containing 0.2 parts of common salt and 0.3 parts of pepsin, adjusted to pH 1.5 with hydrochloric acid) and reacted with stirring in a constant temperature bath at 37°C for 1 to 5 hours. Anti-1; +Tt
After adjusting the pH to 7.0, the bifidus viability was measured by a conventional method. The results are shown in Table 2.
第２表 但しビフィズス固数は顆粒１７換痺数聰である。Table 2 However, the bifidus solid number is 17 granules.
上辰の如く得られた生閣数は実、験誤差内の変動で実質
的に死ｒｔｃ ｊＪ数は全くないといって差支えない。In fact, it is safe to say that the number of living cabinets obtained as above is due to fluctuations within experimental error and there is virtually no dead number of rtc jj at all.
又、小腸内に達すると消化液により油脂膜に）は消化さ
れ、顆粒も崩壊するので消化液の影響により多少の制の
死滅はある。本発明者らが人工腸液で行なった試験では
約２０％の死滅であるので大部分のビフィズス菌は生き
た状態で大腸に達することができる。Furthermore, when it reaches the small intestine, it is digested by the digestive juices (into an oily film) and the granules also disintegrate, so there is some degree of death due to the influence of the digestive juices. In tests conducted by the present inventors using artificial intestinal fluid, approximately 20% of the Bifidobacteria were killed, so most of the Bifidobacteria can reach the large intestine alive.
上記の実験はビフィズス閑についてであるが、本発明の
方法は乳酸菌、酵母直をはじめ多くのｒ散生物の乾燥に
応用することができ、得られた菌体はアルギン酸カルシ
ウムの如き保護膜で薄く且つ均一に被覆されているので
、そのま＼保存しても中性、酸性の高水分の食品中へ添
加しても形崩れはなく、食品中の水分の影響を受けるこ
とも少なく、従来の置体乾燥物にくらべ長期にわたり活
性を糸ａ２持させることができるのである。Although the above experiment was conducted on bifidus, the method of the present invention can be applied to the drying of many prophylactic organisms, including lactic acid bacteria and yeast. In addition, since it is coated uniformly, it will not lose its shape even if it is stored as is or added to neutral or acidic foods with high moisture content, and it is less affected by the moisture in the food, making it easier to use than conventional It is possible to maintain the activity of the yarn a2 for a long period of time compared to the dried product.
以下実施例により説明する。This will be explained below using examples.
実施例１
ヒフイド・バクテリウム・ロンガム（ＢｌｆＩｄｂａｃ
ｔｅｒｉｕｍ Ｉｏｎｇｕｍ）ｉタナシナーゼ（商醋名
）で分解した脱脂乳培地で１８時間３７℃で嫌気培養し
、培養後遠心分離機により歯体を濃縮した。濃縮液はは
ソもとの量になるよう生理食塩水を加え再度遠心分離を
行なって洗滌し、２回洗滌を繰返して培地］、 Ｏｌ当
シ約７００７の生菌体（固形物として約１４０ ｆ ）
ｋ得た。Example 1 Hifidobacterium longum (BlfIdbac
The tooth bodies were cultured anaerobically at 37° C. for 18 hours in a skimmed milk medium digested with T. terium Iongum) i thanasinase (trade name), and after the culture, the tooth bodies were concentrated using a centrifuge. Add physiological saline to the concentrated solution to the original volume, centrifuge it again, wash it, repeat the washing twice, and culture it. f)
I got k.
上記生唾体７００ｔに対し馬鈴薯でん粉２００２、グル
タミン酸モノナトリウム２ Ｏｆ 、Ｌ−アスコルビン
酸ナトリウム１０１−加え、更に予め溶解しておいたア
ルギン酸ナトリウム２５％溶液２００ｍｅ”を加え全体
を均一に混合した。To 700 tons of the raw saliva, 2002 tons of potato starch, 2 Of monosodium glutamate, and 101 tons of sodium L-ascorbate were added, and 200 me'' of a 25% sodium alginate solution dissolved in advance was added and the whole was mixed uniformly.
上記混合液状物を第１図に示す装置で内径０３連続的に
押し出し顆粒状に凝固させた。これを３２メソシユの金
＝ｉ、ｌ）３のスクリーンで掬い取り、水を噴霧して洗
滌後充分脱水し、金属トレー上に５〜１０關の厚さに広
げて凍結乾燥した。得られた顆粒の平均粒径は約Ｑ、
９ ｍｍであシ、比溶’）ｆ＃ ２．７５ ｎｒ１３
／ ？、水分２０チの白色の顆粒で収量は３４０２であ
った。The above-mentioned liquid mixture was continuously extruded using the apparatus shown in FIG. 1 and coagulated into granules. This was scooped out with a screen of 32 mesioles of gold = i, l)3, washed with water and sufficiently dehydrated, spread on a metal tray to a thickness of 5 to 10 degrees and freeze-dried. The average particle size of the obtained granules is approximately Q,
9 mm, specific solubility) f# 2.75 nr13
/ ? The yield was 3,402 ml of white granules with a water content of 20 g.
上記ビフィズス菌顆粒中にはビフィズス直５．８×１０
８個／７含んでおり、密封貯蔵すると長期にわたり活性
を維持し、ヨーグルト等の食品への添加物として好適で
あった。The above bifidobacteria granules contain 5.8 x 10 bifidobacteria.
It contained 8/7 and maintained its activity for a long time when stored in a sealed container, making it suitable as an additive to foods such as yogurt.
実施例２
牛乳ホエーのプロテアーゼ分解物１．０％’！ｚ含むｐ
Ｈ６，２の培地を使用し、ストレプトコッカス・ザー
モ７４ ラス（Ｓｔ 、ｔｈｅｒｍｏｐｈｉ ｌｕｓ
）ｉ４Ｑ°Ｃで４時間培養し、実施例１と同様に遠心分
離、洗滌全行なって培地１０１当たり閑体約７００２（
固形物として約１５０１’！＆得た。Example 2 Milk whey protease decomposition product 1.0%'! p including z
Using H6,2 medium, Streptococcus thermophilus 74 (St, thermophilus
) i4Q°C for 4 hours, centrifuged and washed in the same manner as in Example 1, yielding about 7,002 sludge cells per 101 medium (
Approximately 1501' as a solid! &Obtained.
上記菌体を実施例１と同様な方法で保護膜形成溶液と混
合し、造粒後凍結乾燥し、平均粒形約１０ｍｍ比容積２
．７５ｍｌ／ ｙ、水分２．０％の白色の顆粒３５０７
を得た。The above bacterial cells were mixed with a protective film forming solution in the same manner as in Example 1, granulated and freeze-dried to give an average particle size of about 10 mm and a specific volume of 2.
．． 75ml/y, water 2.0% white granules 3507
I got it.
上記顆粒は］、、 ２ Ｘ １０” イＢｉ！＃の菌数
全台み通気性、透湿性のないアルミ箔で包装後保存試験
をした結果、第３表に示す結果を得た。The above-mentioned granules had a bacterial count of 2 x 10"Bi!#. After packaging with aluminum foil that is not breathable or moisture permeable, the granules were subjected to a storage test, and the results shown in Table 3 were obtained.
第３表
実施例３
実施例１の方法により得たビフィドバクテリウム−ｏン
ガム（１３ｉｆｉｄｂａｃｔｅｒｉｕｍ Ｉｏｎｇｕｍ
）の誦体７００りに対し、馬玲曹でん粉４００７、グル
タミン酸ナトリウム２０７、Ｌ−アスコルビン酸ナトリ
ウム１０！ｉ′、５％のローメトキシル・ペクチン１０
０＃Ｃ加え均一に混合した。Table 3 Example 3 Bifidobacterium Iongum obtained by the method of Example 1
) for 700 recitations, Ma Lingcao starch 4007, monosodium glutamate 207, and sodium L-ascorbate 10! i', 5% rhomethoxyl pectin 10
0#C was added and mixed uniformly.
上記混合液を実施例１と同様にして内径０．４． ｍｍ
のノズルから１係の乳酸カルシウム溶液に５１＋の高さ
から射出して造粒させ３２メソシユのスクリーンで掬い
取り、流水で洗滌後充分脱水し、凍結乾燥し、平均粒径
１ ｍｍ比容潰３．０ ｍｌ ／ ｆ、水分２０係の白
色の顆粒５３０２を得た。この顆粒中のビフィズス画数
は２．ＯＸ ］、 ０８１固／・２であり、長期保存に
適した。The above mixed solution was prepared in the same manner as in Example 1, and the inner diameter was 0.4. mm
The granules were injected from a height of 51+ into a 1st part calcium lactate solution from a nozzle, scooped out with a 32 sieve screen, washed with running water, thoroughly dehydrated, freeze-dried, and crushed to an average particle size of 1 mm by specific volume. White granules 5302 with a water content of .0 ml/f and a moisture content of 20 parts were obtained. The number of bifidus strokes in this granule is 2. OX], 081 hardness/・2, and is suitable for long-term storage.
実施例４
ザノカロミセス・セレビソシエ（Ｓａｃ 、Ｃｅ！ ｌ
ｅｖ ｉ ｃａｅ ） ｆ甘蔗糖蜜培地で３０℃で通気
培養し、遠心分離・洗滌して＞＠に’−”当たシ約７０
０ｆｌＯ生繭体を得た。Example 4 Zanocalomyces cerevisociae (Sac, Ce! l
ev i cae) f Aerated culture at 30°C in cane molasses medium, centrifuged and washed to reach a concentration of about 70
0flO live cocoons were obtained.
上記菌体をコーンスターチ２００Ｆ、５％ローメトキシ
ルペクチン１０００１１１１と混合し、実施例１と同僚
にして内径０．５ ｍ＋πのノズルから７ｃｍｍの高さ
から押し出し、造粒し、３２メツシーのスクリーンで掬
い出した後光分水洗し、真仝乾燥して平均粒径１．２
＋ｉ１ｍｘ水分５０％の顆粒約４．５０ｆ’ｅ得た。こ
の顆粒は長期医存しても発酵力全欠うことはなかった。The above bacterial cells were mixed with corn starch 200F and 5% rhomethoxyl pectin 10001111, extruded from a height of 7 cm from a nozzle with an inner diameter of 0.5 m + π in the same manner as in Example 1, granulated, and scooped out with a 32 mesh screen. After that, it was washed with light and water, and then truly dried to obtain an average particle size of 1.2.
Approximately 4.50 f'e of granules with +i1 m x 50% moisture were obtained. These granules did not lose their fermentation ability even after long-term medical treatment.
第１図は装置の説明図、第２図は第１図の凝固液槽の断
面図、第３図はコーティングした顆粒の１所面拡大図で
ある。
１・・・混合槽 ４ 貯槽
６．８・・・配管 １０−ノズル
］２・・・凝固液槽 １４・・・凝固液貯槽１６・・・
スクリーン ２０ ・容器
Ａ・混合物 Ｂ・凝固液
Ｃ・・・凝固粒子
特許出願人
明治乳業株式会社FIG. 1 is an explanatory diagram of the apparatus, FIG. 2 is a cross-sectional view of the coagulating liquid tank of FIG. 1, and FIG. 3 is an enlarged view of one part of the coated granules. 1...Mixing tank 4 Storage tank 6.8...Piping 10-nozzle] 2...Coagulation liquid tank 14...Coagulation liquid storage tank 16...
Screen 20 ・Container A ・Mixture B ・Coagulation liquid C...Coagulation particle patent applicant Meiji Dairies Co., Ltd.
Claims (4)
固用塩類溶液に注入して凝固させ、得られた凝固物を取
シ出して乾燥し、必要に応じて体温以上の融点をもつ油
脂でコーティングすることを特徴とする固体顆粒の製造
方法。(1) Mix viable bacterial cells and a protective film-forming solution, inject the mixed solution into a saline solution for total coagulation to coagulate, take out the coagulated product, dry it, and if necessary, heat it to a temperature above body temperature. A method for producing solid granules, characterized by coating them with an oil or fat having a melting point.
許請求の範囲第１項の菌体顆粒の製造方法。(2) The method for producing bacterial granules according to claim 1, wherein the living box is made of bifidobacteria.
、菌体５〜１０部、でん粉１０〜５０部、アルギン酸ナ
トリウム０１〜１．０部を含むことを特徴とする特許請
求の範囲第１項の菌体顆粒製造方法。(3) The mixture of the living box and the protective film forming solution contains 5 to 10 parts of bacterial cells, 10 to 50 parts of starch, and 01 to 1.0 parts of sodium alginate in terms of dry weight ratio. The method for producing bacterial cell granules according to Scope 1.
貯槽と連通し下方に向けて垂下するノズルと、該ノズル
の下方に液面が位置するよう設けた凝固槽と、前記ノズ
ルの噴出量を調節する装置よシなり、前記ノズルは内径
１龍以下好ましくは０２〜０、５ ｍであり、前記ノズ
ルの先端と前記凝固槽の液面間隔が約３〜１０ＣＴＬで
あることを特徴とする函体顆粒の製造装置。(4) Living cocoon and protection: a storage tank that stores all of the protective film forming solution, a nozzle that communicates with the storage tank and hangs downward, a coagulation tank that is provided so that the liquid level is located below the nozzle, and Depending on the device for adjusting the jetting amount of the nozzle, the nozzle has an inner diameter of 1 mm or less, preferably 0.2 to 0.5 m, and the liquid level distance between the tip of the nozzle and the coagulation tank is about 3 to 10 CTL. A box granule manufacturing device characterized by:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24539883A JPS60141281A (en) | 1983-12-28 | 1983-12-28 | Method and apparatus for producing granule of microorganism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24539883A JPS60141281A (en) | 1983-12-28 | 1983-12-28 | Method and apparatus for producing granule of microorganism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60141281A true JPS60141281A (en) | 1985-07-26 |
| JPS6148916B2 JPS6148916B2 (en) | 1986-10-27 |
Family
ID=17133056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24539883A Granted JPS60141281A (en) | 1983-12-28 | 1983-12-28 | Method and apparatus for producing granule of microorganism |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60141281A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61149152A (en) * | 1984-12-24 | 1986-07-07 | 大正製薬株式会社 | Apparatus for producing seamless capsule |
| JP2000300211A (en) * | 1999-04-21 | 2000-10-31 | Risoo Erudesu:Kk | Health food composition formulated with metabolic product of lactobacillus |
| JP2007515182A (en) * | 2003-12-23 | 2007-06-14 | コンパニー ジェルヴェ ダノン | Foods containing lactic acid bacteria granules |
| JP2012518027A (en) * | 2009-02-19 | 2012-08-09 | ユーリア カサーレ ソシエテ アノニム | Granules containing filamentous fungi and method for preparing the same |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55157502A (en) * | 1979-03-28 | 1980-12-08 | Damon Corp | Live tissue encapsulation and tissue transplantation |
| JPS5816693A (en) * | 1981-03-13 | 1983-01-31 | デイモン・バイオテック・インコ−ポレ−テッド | Production of substance produced by bacteria |
-
1983
- 1983-12-28 JP JP24539883A patent/JPS60141281A/en active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55157502A (en) * | 1979-03-28 | 1980-12-08 | Damon Corp | Live tissue encapsulation and tissue transplantation |
| JPS5816693A (en) * | 1981-03-13 | 1983-01-31 | デイモン・バイオテック・インコ−ポレ−テッド | Production of substance produced by bacteria |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61149152A (en) * | 1984-12-24 | 1986-07-07 | 大正製薬株式会社 | Apparatus for producing seamless capsule |
| JPH0467985B2 (en) * | 1984-12-24 | 1992-10-30 | Taisho Pharma Co Ltd | |
| JP2000300211A (en) * | 1999-04-21 | 2000-10-31 | Risoo Erudesu:Kk | Health food composition formulated with metabolic product of lactobacillus |
| JP2007515182A (en) * | 2003-12-23 | 2007-06-14 | コンパニー ジェルヴェ ダノン | Foods containing lactic acid bacteria granules |
| JP2012518027A (en) * | 2009-02-19 | 2012-08-09 | ユーリア カサーレ ソシエテ アノニム | Granules containing filamentous fungi and method for preparing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6148916B2 (en) | 1986-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6820340B2 (en) | Coating method of lactic acid bacteria with enhanced intestinal survival rate | |
| JPS60221078A (en) | Granular product of useful microorganism powder and its preparation | |
| CN103458709B (en) | Microencapsulation prebiotic substances and its manufacture method | |
| JP5576606B2 (en) | Composition for enteral administration of microorganisms | |
| CN107997179A (en) | A kind of preparation method of lactobacillus micro-capsule | |
| CN104543611A (en) | Application of whey protein and reducing oligosaccharide Maillard product to microcapsule wall materials and embedded probiotics | |
| JPH0195726A (en) | Reconstructive dryed product for direct ingestion and method for its manufacture | |
| Nezamdoost-Sani et al. | Alginate and derivatives hydrogels in encapsulation of probiotic bacteria: An updated review | |
| EP1514553B1 (en) | Lactic acid bacteria powder double-coated using protein and polysaccharide and method preparing the same and a dosage form thereof | |
| JPS60141281A (en) | Method and apparatus for producing granule of microorganism | |
| CN109864137A (en) | A kind of quick-fried pearl Yoghourt and preparation method thereof | |
| JP2001245660A (en) | Capsule including live cell or tissue | |
| JP2968089B2 (en) | Coating material and enteric-coated granules using the same | |
| CN1440758A (en) | Bioactive hill wasp powder and its prepn | |
| JP3187502B2 (en) | Enteric granules | |
| JPH05186337A (en) | Enteric granule composed of multiple granules | |
| WO2019144979A1 (en) | Method for granulating and coating probiotics and granulated core obtained using same | |
| JP2005171200A (en) | Cellulose molded product | |
| KR100473391B1 (en) | Powder of lactic acid bacteria having improved physiological characteristics and method of preparing the same | |
| JPH05186336A (en) | Enteric particle | |
| JPH01196280A (en) | Polyfunctional food and production thereof | |
| CN107821605A (en) | A kind of band fish protein peptide Nutrious milk powder and preparation method thereof | |
| KR100846672B1 (en) | Improved productivity and survival of bacillus polyfermenticus scd by alginate/methyl-cellulose encapsulelation and use thereof | |
| KR102163637B1 (en) | Method for producing functional health food | |
| KR20240001347A (en) | Vegetable marshmallow containing lactic acid bacteria and manufacturing method |